1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S , Mathers C et al. Globocan 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globcan.iarc.fr . Accessed on 20 Jul 2014.
2. Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force. Rockville: Recommendation Agency for Healthcare Research and Quality (US); 2013.
3. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe, 1999–2007 by country and age: results of EUROCARE-5 a population based study. Lancet Oncol. 2014;15:23–34.
4. Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:169–71.
5. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, Mcintosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.